A Prospective, Open Label, Non-comparative Trial to Determine the Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients.

Trial Profile

A Prospective, Open Label, Non-comparative Trial to Determine the Incidence of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With the Docetaxel-Cyclophosphamide Regimen in Early Breast Cancer Patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2016

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone; Granisetron; Ondansetron; Tropisetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Mar 2016 Results (n = 185) published in the European Journal of Cancer.
    • 18 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jun 2013 Planned End Date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top